German Science & Technology Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on German Science & Technology Today.

Press releases published on September 14, 2026

Sep. 14, 2026

EU Product Pass Compliance Made Simple: DPP-Flash Launches AI Platform for SMEs

Indeterminate EIN Presswire

Sep. 14, 2026

GECCO and enclaive bring confidential computing and post-quantum-ready encryption to rugged edge deployments

Indeterminate EIN Presswire

Sep. 14, 2026

COnovate Wins $1.25M DOE Contract to Scale U.S. Graphite-Alternative Anode Production

Indeterminate EIN Presswire

Sep. 14, 2026

Industry Networks Merge into Single Pair Ethernet Association

Indeterminate EIN Presswire

Sep. 14, 2026

AEMOB FORUM 2026 CLOSES IN DOHA WITH MORE THAN 1,500 ATTENDEES, 71 SPEAKERS AND 33 EXHIBITORS

Indeterminate EIN Presswire

Sep. 14, 2026

NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications

Indeterminate GlobeNewswire

Sep. 14, 2026

Roger Spitz Ranked #6 on Thinkers360’s 2026 Management Leaderboard as Foresight Enters Management Practice

Indeterminate EIN Presswire

Sep. 14, 2026

SMOXH Builds Production Around In-House Heat Treatment and Plans Further Plant Investment

Indeterminate EIN Presswire

Sep. 14, 2026

ZEISS VersaXRM 5 Insight beschleunigt hybrides 3D-Röntgen-Imaging

Indeterminate GlobeNewswire

Sep. 14, 2026

ZEISS VersaXRM 5 Insight accelerates hybrid 3D X-ray imaging

Indeterminate GlobeNewswire

Sep. 14, 2026

BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients

Indeterminate GlobeNewswire

Sep. 14, 2026

Neue Daten zu Gotistobart zeigten annähernde Verdopplung des medianen Gesamtüberlebens im Vergleich zur Standardchemotherapie bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge

Indeterminate GlobeNewswire

Sep. 14, 2026

Basileas Partner Asahi Kasei Therapeutics startet klinische Studie mit Antipilzmittel Cresemba® (Isavuconazol) bei Kindern in Japan

Indeterminate GlobeNewswire

Sep. 14, 2026

Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients

Indeterminate GlobeNewswire